GSK3β peptide
Description
Application Data
Description
-
Antigenic peptide of GSK3β, a ubiquitously expressed mammalian multifunctional serine/threonine kinase
Application Data
-
Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1200462 Antibody GSK3β peptide Antigen Peptide GSK-3β peptide Protein ID UniProtKB - P49841 Aliases Glycogen synthase kinase-3 beta, GSK3 beta, GSK3B, Serine/threonine-protein kinase GSK3B Cross-Reactivity Human Target Protein Species Human Storage Stabilisers -20°C Specificity Protein Storage -20°C Citations Gao, S., Li, S., Duan, X., Gu, Z., Ma, Z., Yuan, X., Feng, X. and Wang, H. (2017). Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of oesophageal squamous cell carcinoma by modifying STAT3 activity. Mol Carcinog, 56(10), 2301-2316. PMID: 28574599
Zeng, J., Liu, D., Qiu, Z., Huang, Y., Chen, B., Wang, L., Xu, H., Huang, N., Liu, L. and Li, W. (2014). GSK3β Overexpression Indicates Poor Prognosis and Its Inhibition Reduces Cell Proliferation and Survival of Non-Small Cell Lung Cancer Cells. PLoS ONE, 9(3), e91231. PMID: 24618715
References Gao, S., Li, S., Duan, X., Gu, Z., Ma, Z., Yuan, X., Feng, X. and Wang, H. (2017). Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of oesophageal squamous cell carcinoma by modifying STAT3 activity. Mol Carcinog, 56(10), 2301-2316. PMID: 28574599
Zeng, J., Liu, D., Qiu, Z., Huang, Y., Chen, B., Wang, L., Xu, H., Huang, N., Liu, L. and Li, W. (2014). GSK3β Overexpression Indicates Poor Prognosis and Its Inhibition Reduces Cell Proliferation and Survival of Non-Small Cell Lung Cancer Cells. PLoS ONE, 9(3), e91231. PMID: 24618715
Glycogen Synthase Kinase 3 beta (GSK3β) is a multifunctional serine/threonine kinase widely expressed in most mammalian cells. GSK3β is highly active under basal conditions and acts downstream of phosphoinositide 3-kinase (PI3K) signalling. PI3K activation results in Akt phosphorylation and the subsequent phosphorylation of GSK3β at serine-9 and its inactivation. GSK3β in turn activates the production of pro-inflammatory cytokines including IL-1β, IL-6, IL-12, IL-17, TNFα and IFNγ, and supresses the production of IL-10, IL-1Ra, and IFNβ by immune cells.
Under resting conditions, GSK3β is constitutively active due to tyrosine-216 phosphorylation, and it phosphorylates and inhibits a diverse group of pro-oncogenic substrates, such as: β-catenin; cyclin D1; c-Jun; c-Myc and CREB. GSK3β is also involved in Wnt signalling pathways.
Aberrant expression of GSK3β has been shown to promote cell growth in some cancers and to suppress it in others. GSK3β inhibition leads to the accumulation of β-catenin in the nucleus, enhancing the progression of many cancers. However the inhibition of GSK3β also induces apoptosis in various types of cancers, such as pancreatic, colorectal and bladder cancer. Inhibition of GSK3β can also have neuroprotective effects on dopaminergic neurons such as in Parkinson’s disease.